Which has the lower trailing P/E, AMRX or KNSA?

AMRX has the lower trailing P/E: AMRX trades at 41.93 and KNSA at 77.65. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, AMRX or KNSA?

Over the past five years, KNSA grew revenue faster — AMRX at a 8.67% CAGR versus KNSA at 155.66%.

Is AMRX or KNSA more profitable?

KNSA runs the higher net margin — AMRX at 5.05% versus KNSA at 9.59%.

How have AMRX and KNSA total returns compared?

Over the past 5 years, AMRX delivered 30.25% and KNSA delivered 47.48% annualized total return. Past performance doesn't predict future results.

Amneal Pharmaceuticals, Inc. (AMRX) vs Kiniksa Pharmaceuticals International, plc (KNSA)

A side-by-side comparison of Amneal Pharmaceuticals, Inc. and Kiniksa Pharmaceuticals International, plc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AMRX

Amneal Pharmaceuticals, Inc.

$6.53B

$20.44HealthcareDelayed quote: Oct 6, 2026, 12:05 PM EDT

KNSA

Kiniksa Pharmaceuticals International, plc

$5.80B

$76.10HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT

Total return — AMRX vs KNSA

growth of $100 · dividends reinvested · last 8y

AMRX +18.5% (+2.1%/yr)KNSA +291.9% (+18.6%/yr)KNSA compounded faster over this window

AMRX KNSA

AMRX vs KNSA: by the numbers

•AMRX is the larger company ($6.53B vs $5.80B market cap).
•AMRX trades at the lower trailing earnings multiple (41.93 vs 77.65 P/E), one valuation lens rather than an overall verdict.
•KNSA converts more revenue to profit (9.59% vs 5.05% net margin).
•KNSA grew revenue faster over the past five years (155.66% vs 8.67% CAGR).

Metrics side by side

Valuation

Metric	AMRX	KNSA
P/E ratio	41.93	77.65
Forward P/E	19.97	54.64
P/S ratio	2.09	6.90
P/B ratio	197.65	8.87
EV / EBITDA	15.38	55.20
FCF yield	1.27%	3.16%

Profitability

Metric	AMRX	KNSA
Gross margin	39.32%	54.49%
Operating margin	12.93%	11.92%
Net margin	5.05%	9.59%
ROE	476.51%	12.33%
ROIC	13.45%	9.76%

Growth (annualized)

Metric	AMRX	KNSA
Revenue CAGR (5Y)	8.67%	155.66%
EPS CAGR (5Y)	-17.72%	N/A
FCF CAGR (5Y)	-14.46%	N/A
Total return CAGR (5Y)	30.25%	47.48%

Frequently asked

Which has the lower trailing P/E, AMRX or KNSA?: AMRX has the lower trailing P/E: AMRX trades at 41.93 and KNSA at 77.65. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, AMRX or KNSA?: Over the past five years, KNSA grew revenue faster — AMRX at a 8.67% CAGR versus KNSA at 155.66%.
Is AMRX or KNSA more profitable?: KNSA runs the higher net margin — AMRX at 5.05% versus KNSA at 9.59%.
How have AMRX and KNSA total returns compared?: Over the past 5 years, AMRX delivered 30.25% and KNSA delivered 47.48% annualized total return. Past performance doesn't predict future results.

Go deeper

Full AMRX analysis Full KNSA analysis Interactive comparison tool

Dig into the metrics

Amneal Pharmaceuticals P/E ratio Kiniksa Pharmaceuticals International P/E ratio Amneal Pharmaceuticals ROE Kiniksa Pharmaceuticals International ROE Amneal Pharmaceuticals operating margin Kiniksa Pharmaceuticals International operating margin Amneal Pharmaceuticals revenue growth Kiniksa Pharmaceuticals International revenue growth Amneal Pharmaceuticals free cash flow Kiniksa Pharmaceuticals International free cash flow

Amneal Pharmaceuticals & Kiniksa Pharmaceuticals International appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.